IMV Inc. (IMV) Provides Update and Planned 2023 Milestones for MVP-S
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St ends higher as stocks reclaim some shine
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Snowflake soars 20% on earnings beat and raised guidance
- Oil settles 1% higher, as US-Iran strikes threaten supplies
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S
January 8, 2023 5:00 PM ESTPresenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023
Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023
Recently strengthened financial position with the completion of a $9M financing
Appoints Shabnam Kazmi to its Board of Directors following the retirement of Julia P. Gregory
DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV) (IMV or the Company), a clinical-stage... More
